Clinical Remission Rates in Patients With Epithelial Ovarian Cancer Before and After the Onset of the COVID 19 Pandemic in an Integrated Healthcare Delivery System.

IF 2.5 4区医学 Q3 ONCOLOGY

Cancer Management and Research Pub Date : 2025-02-12 eCollection Date: 2025-01-01 DOI:10.2147/CMAR.S487894

Amrita Mukherjee, Natalie Ayoub, Lanfang Xu, Kimberly L Cannavale, Alec D Gilfillan, Elizabeth A Szamreta, Matthew J Monberg, Melissa Hodeib, Chun R Chao

{"title":"Clinical Remission Rates in Patients With Epithelial Ovarian Cancer Before and After the Onset of the COVID 19 Pandemic in an Integrated Healthcare Delivery System.","authors":"Amrita Mukherjee, Natalie Ayoub, Lanfang Xu, Kimberly L Cannavale, Alec D Gilfillan, Elizabeth A Szamreta, Matthew J Monberg, Melissa Hodeib, Chun R Chao","doi":"10.2147/CMAR.S487894","DOIUrl":null,"url":null,"abstract":"Purpose: Evidence on the impact of the coronavirus disease 2019 (COVID-19) pandemic on outcomes in patients with ovarian cancer patients is limited. We compared remission outcomes in patients with ovarian cancer before and during the pandemic.Patients and methods: This retrospective cohort study included patients diagnosed with epithelial ovarian cancer between 01/01/2017 and 06/30/2021 at Kaiser Permanente Southern California. Pre and post pandemic periods were designated using March 4, 2020, as the cut-off. Stage I-IV patients who completed chemotherapy and/or surgery as first-line treatment were included. Data on remission outcomes (complete and clinical remission) were abstracted by manual chart reviews. Complete remission was defined as no evidence of disease; clinical remission included both complete and partial response to treatment. Modified Poisson regression was used to evaluate the association of pandemic and remission. Effect modification by race/ethnicity was evaluated.Results: Of 748 ovarian cancer patients included, 72.7% and 27.3% patients were diagnosed before and during the pandemic, respectively. Complete remission was observed in 75.7% and 73.5% patients before and during the pandemic, respectively (p = 0.53). No statistically significant association of pandemic period with remission outcomes was observed in the adjusted models. However, race/ethnicity modified the association of pandemic period with complete remission (p-value < 0.01). White patients, but not other racial/ethnic groups, were 13% more likely to achieve complete remission during the pandemic than during the pre-pandemic [adjusted rate ratio (95% confidence interval): 1.13 (1.00-1.28)].Conclusion: Patients diagnosed with ovarian cancer achieved similar complete and clinical remission rates before and during the pandemic. Association of the pandemic period with complete remission varied for White vs non-White patients.","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"281-291"},"PeriodicalIF":2.5000,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11830944/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Management and Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/CMAR.S487894","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Evidence on the impact of the coronavirus disease 2019 (COVID-19) pandemic on outcomes in patients with ovarian cancer patients is limited. We compared remission outcomes in patients with ovarian cancer before and during the pandemic.

Patients and methods: This retrospective cohort study included patients diagnosed with epithelial ovarian cancer between 01/01/2017 and 06/30/2021 at Kaiser Permanente Southern California. Pre and post pandemic periods were designated using March 4, 2020, as the cut-off. Stage I-IV patients who completed chemotherapy and/or surgery as first-line treatment were included. Data on remission outcomes (complete and clinical remission) were abstracted by manual chart reviews. Complete remission was defined as no evidence of disease; clinical remission included both complete and partial response to treatment. Modified Poisson regression was used to evaluate the association of pandemic and remission. Effect modification by race/ethnicity was evaluated.

Results: Of 748 ovarian cancer patients included, 72.7% and 27.3% patients were diagnosed before and during the pandemic, respectively. Complete remission was observed in 75.7% and 73.5% patients before and during the pandemic, respectively (p = 0.53). No statistically significant association of pandemic period with remission outcomes was observed in the adjusted models. However, race/ethnicity modified the association of pandemic period with complete remission (p-value < 0.01). White patients, but not other racial/ethnic groups, were 13% more likely to achieve complete remission during the pandemic than during the pre-pandemic [adjusted rate ratio (95% confidence interval): 1.13 (1.00-1.28)].

Conclusion: Patients diagnosed with ovarian cancer achieved similar complete and clinical remission rates before and during the pandemic. Association of the pandemic period with complete remission varied for White vs non-White patients.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Management and Research Medicine-Oncology

CiteScore

7.40

自引率

0.00%

发文量

448

审稿时长

16 weeks

期刊介绍： Cancer Management and Research is an international, peer reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for cancer patients. Specific topics covered in the journal include: ◦Epidemiology, detection and screening ◦Cellular research and biomarkers ◦Identification of biotargets and agents with novel mechanisms of action ◦Optimal clinical use of existing anticancer agents, including combination therapies ◦Radiation and surgery ◦Palliative care ◦Patient adherence, quality of life, satisfaction The journal welcomes submitted papers covering original research, basic science, clinical & epidemiological studies, reviews & evaluations, guidelines, expert opinion and commentary, and case series that shed novel insights on a disease or disease subtype.